A quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Ying Zhou1,2, Xiaoyan Xue3, Yanyan Guo4
1Department of Basic Medicine, Xi'an Medical University, Xi'an 710021, PR China.
Experimental Biology and Medicine (Maywood, N.J.)
|July 26, 2021
Summary
6,7-dichloro-2-methylsulfonyl-3-Ntert-butylaminoquinoxaline (DMB), a GLP-1R agonist, combats osteoporosis by boosting bone formation. This small molecule compound shows promise for managing postmenopausal osteoporosis.
Area of Science:
- Pharmacology
- Endocrinology
- Bone Biology
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are explored for therapeutic potential beyond glycemic control.
- Osteoporosis, particularly postmenopausal osteoporosis, remains a significant health concern requiring novel therapeutic strategies.
Purpose of the Study:
- To investigate the anti-osteoporosis effects of 6,7-dichloro-2-methylsulfonyl-3-Ntert-butylaminoquinoxaline (DMB), a GLP-1R agonist.
- To elucidate the mechanisms underlying DMB's impact on bone metabolism in an osteoporotic mouse model.
Main Methods:
- An ovariectomy (OVX)-induced osteoporosis mouse model was established.
- Mice were treated with DMB, exendin-4 (EX-4), or 17β-estradiol (E2) for two months.
- Bone mass, structure, biomechanical strength, bone turnover markers, and histomorphometry were analyzed using micro-CT and other assays.
Main Results:
- DMB and EX-4 treatments inhibited skeletal deterioration and enhanced femur biomechanical strength in OVX mice.
- Both DMB and EX-4 increased osteoblast numbers and bone formation markers while decreasing osteoclast numbers and bone resorption markers.
- DMB treatment stimulated osteoblastogenesis-related gene expression, indicating a mechanism of action via enhanced bone formation.
Conclusions:
- DMB ameliorates bone loss in an osteoporosis model primarily by inducing bone formation.
- DMB demonstrates potential as a therapeutic agent for managing postmenopausal osteoporosis.
Related Concept Videos
01:17Hormones and Bone Tissue
3.2K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.2K
01:31Osteoclasts in Bone Remodeling
3.4K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.4K